8-K: Protara Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Protara Therapeutics announced its second quarter 2024 financial results, highlighted by progress in its TARA-002 and IV Choline Chloride programs, and expects cash resources to fund operations into 2026.

Summary

• Protara Therapeutics reported its financial results for the second quarter of 2024, showing a net loss of $9.5 million, or $0.45 per share, compared to a net loss of $11.3 million, or $1.00 per share, for the same period in 2023.
• The company's cash resources are approximately $90 million, which includes net proceeds from an April 2024 private placement, and are expected to fund operations into 2026.
• Research and development expenses decreased to $6.4 million from $7.2 million year-over-year, primarily due to a decrease in non-clinical and clinical trial expenses related to TARA-002.
• General and administrative expenses decreased to $4.3 million from $4.9 million year-over-year, mainly due to a reduction in personnel-related expenses and market development activities.
• The company is on track to report preliminary data from six-month evaluable patients in the ADVANCED-2 trial of TARA-002 in non-muscle invasive bladder cancer (NMIBC) in the fourth quarter of 2024.
• Protara expects to dose the first patient in a pivotal trial for IV Choline Chloride in the first quarter of 2025.
• Enrollment continues in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric patients with lymphatic malformations (LMs).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the company's progress in clinical trials, strong cash position, and alignment with the FDA. However, the company is still incurring losses and faces risks associated with clinical development and funding.

Positives

• The company's cash position is strong, with approximately $90 million expected to fund operations into 2026.
• There has been a reduction in both research and development and general and administrative expenses year-over-year.
• The company is progressing with its clinical trials for TARA-002 in NMIBC and LMs, and IV Choline Chloride.
• Protara has aligned with the FDA on a registrational path forward for IV Choline Chloride.
• The company has shown manufacturing comparability between TARA-002 and OK-432.

Negatives

• The company reported a net loss of $9.5 million for the second quarter of 2024.
• The company is still in the clinical trial phase and has not yet generated revenue from product sales.

Risks

• The company's financial guidance may not be as expected.
• There are risks associated with the development programs, including the initiation and completion of clinical trials and the timing of required filings with the FDA.
• The company's ability to obtain sufficient financing to fund its strategic plans and commercialization efforts is a risk.
• There are risks associated with general market conditions, changes in the competitive landscape, and changes in the company's strategic and commercial plans.
• The company may have to use cash in ways or on timing other than expected.
• Market volatility could impact cash reserves.
• Failure to attract and retain management and key personnel is a risk.
• General U.S. and foreign economic, industry, market, regulatory, political or public health conditions could impact the company.

Future Outlook

The company expects its cash resources to fund operations into 2026, anticipates reporting preliminary data from the ADVANCED-2 trial in Q4 2024, and plans to begin dosing patients in the pivotal trial for IV Choline Chloride in Q1 2025.

Management Comments

• The first half of the year has been marked by significant progress as we advance our mission to deliver transformative therapies to patients with cancer and rare diseases, said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics.
• We believe our growing clinical dataset continues to support the potential of TARA-002 to serve as a meaningful addition to the NMIBC treatment landscape and look forward to sharing interim data from our ADVANCED-2 trial in the fourth quarter of this year.
• We also continue to focus on identifying the best agent for combination as we believe TARA-002s mechanism of action and safety profile give it strong potential for use in combination therapy in NMIBC.
• Beyond the NMIBC program, we announced alignment with the FDA on a path forward for intravenous (IV) Choline Chloride for patients on long-term parenteral nutrition (PN), and we expect to start dosing patients in our pivotal trial in the first quarter of 2025.

Industry Context

This announcement reflects the ongoing efforts of biotechnology companies to develop new therapies for cancer and rare diseases, with a focus on clinical trial progress and regulatory alignment. The company's focus on NMIBC and LMs aligns with areas of unmet medical need, and the development of IV Choline Chloride addresses a specific deficiency in patients on parenteral nutrition.

Comparison to Industry Standards

• Protara's focus on TARA-002 for NMIBC is comparable to other companies developing novel therapies for this indication, such as CG Oncology with its oncolytic virus therapy, and UroGen Pharma with its mitomycin-containing reverse thermal gel.
• The development of IV Choline Chloride for PN patients is unique, as there are currently no FDA-approved IV choline formulations, giving Protara a potential first-mover advantage in this space.
• The company's cash runway into 2026 is relatively strong compared to other clinical-stage biotech companies, which often face challenges in securing funding for ongoing operations and clinical trials.
• The reported net loss is typical for a clinical-stage biotech company that is not yet generating revenue from product sales, and the decrease in R&D and G&A expenses is a positive sign of cost management.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the company's financial performance and clinical trial progress.
• Employees will be impacted by the company's financial stability and growth prospects.
• Patients with NMIBC, LMs, and those on parenteral nutrition stand to benefit from the development of new therapies.
• The company's suppliers and creditors will be impacted by its financial health and ability to meet its obligations.

Next Steps

• Report preliminary data from six-month evaluable patients in the ADVANCED-2 trial of TARA-002 in NMIBC in Q4 2024.
• Dose the first patient in the pivotal trial for IV Choline Chloride in Q1 2025.
• Continue enrollment in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric patients with LMs.
• Assess higher dosing of TARA-002 at an 80KE1 dose and report data by the end of the year.
• Explore systemic priming dosing prior to initiation of intravesical administration of TARA-002.
• Determine the best possible options for combination therapy with TARA-002 in NMIBC patients with CIS.

Key Dates

Keywords

TARA-002, IV Choline Chloride, NMIBC, Lymphatic Malformations, Clinical Trials, Financial Results, Biotechnology, Rare Diseases, Cancer, FDA